{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:27:09Z","timestamp":1761600429657,"version":"build-2065373602"},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.autrev.2021.102757","type":"journal-article","created":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T22:30:39Z","timestamp":1611009039000},"page":"102757","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Real life picture of the use of intravenous immunoglobulins in idiopathic inflammatory myopathies: Results of a multicentric study"],"prefix":"10.1016","volume":"20","author":[{"given":"Simone","family":"Barsotti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Cavazzana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Zanframundo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rossella","family":"Neri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mara","family":"Taraborelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Cioffi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Cardelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Tripoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica","family":"Codullo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Tincani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Cavagna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franco","family":"Franceschini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Mosca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2021.102757_bb0005","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1056\/NEJMra1402225","article-title":"Inflammatory muscle diseases","volume":"372","author":"Dalakas","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2021.102757_bb0010","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.autrev.2017.07.016","article-title":"How I treat idiopathic patients with inflammatory myopathies in the clinical practice","volume":"16","author":"Cavagna","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102757_bb0015","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40674-018-0106-2","article-title":"Current treatment for myositis","volume":"4","author":"Barsotti","year":"2018","journal-title":"Curr Treat Options Rheumatol"},{"key":"10.1016\/j.autrev.2021.102757_bb0020","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.mayocp.2016.12.025","article-title":"Diagnosis and management of immune-mediated myopathies","volume":"92","author":"Milone","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.autrev.2021.102757_bb0025","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/joim.12511","article-title":"Update on the pharmacological treatment of adult myositis","volume":"280","author":"Oddis","year":"2016","journal-title":"J Intern Med"},{"key":"10.1016\/j.autrev.2021.102757_bb0030","first-page":"880","article-title":"Developing standardised treatment for adults with myositis and different phenotypes: an international survey of current prescribing preferences","volume":"34","author":"Tansley","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2021.102757_bb0035","first-page":"545","article-title":"Course of dermatomyositis-polymyositis: comparison of untreated and cortisone-treated patients","volume":"43","author":"Winkelmann","year":"1968","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.autrev.2021.102757_bb0040","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/1529-0131(200002)43:2<336::AID-ANR13>3.0.CO;2-V","article-title":"Decreased expression of interleukin-1alpha, interleukin-1beta, and cell adhesion molecules in muscle tissue following corticosteroid treatment in patients with polymyositis and dermatomyositis","volume":"43","author":"Lundberg","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2021.102757_bb0045","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1080\/13497413.2018.1481571","article-title":"Myositis an evolving spectrum of disease","volume":"41","author":"Barsotti","year":"2018","journal-title":"Immunol Med"},{"key":"10.1016\/j.autrev.2021.102757_bb0050","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s13311-015-0391-5","article-title":"Efficacy of intravenous immunoglobulin in neurological diseases","volume":"13","author":"L\u00fcnemann","year":"2016","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.autrev.2021.102757_bb0055","doi-asserted-by":"crossref","DOI":"10.1007\/s10875-014-0024-5","article-title":"Mechanistic {Effects} of {IVIg} in {Neuroinflammatory} {Diseases}: {Conclusions} {Based} on {Clinicopathologic} {Correlations}","author":"Dalakas","year":"2014","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.autrev.2021.102757_bb0060","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2021.102757_bb0065","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3109\/s10165-011-0534-4","article-title":"Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial","volume":"22","author":"Miyasaka","year":"2012","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.autrev.2021.102757_bb0070","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/art.10053","article-title":"Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients","volume":"46","author":"Cherin","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2021.102757_bb0075","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/s10165-007-0013-0","article-title":"Efficacy of high-dose intravenous immunoglobulin therapy in Japanese patients with steroid-resistant polymyositis and dermatomyositis","volume":"18","author":"Saito","year":"2008","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.autrev.2021.102757_bb0080","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.autrev.2009.04.003","article-title":"Intravenous immunoglobulin as add on treatment with mycophenolate mofetil in severe myositis","volume":"9","author":"Danieli","year":"2009","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102757_bb0085","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.semarthrit.2016.07.014","article-title":"Critical review of the role of intravenous immunoglobulins in idiopathic inflammatory myopathies","volume":"46","author":"Anh-Tu Hoa","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2021.102757_bb0090","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2021.102757_bb0095","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2021.102757_bb0100","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1378\/chest.10-0180","article-title":"Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years?","volume":"138","author":"Connors","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.autrev.2021.102757_bb0105","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/ana.410380504","article-title":"Inclusion body myositis and myopathies","volume":"38","author":"Griggs","year":"1995","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2021.102757_bb0110","first-page":"S118","article-title":"Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: {Physician} and {Patient}\/{Parent} {Global} {Activity}, {Manual} {Muscle} {Testing} ({MMT}), {Health} {Assessment} {Questionnaire} ({HAQ})\/{Childhood} {Health} {Ass}","volume":"63","author":"Rider","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.autrev.2021.102757_bb0115","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/00002281-199911000-00005","article-title":"Cutaneous features of classic dermatomyositis and amyopathic dermatomyositis","volume":"11","author":"Sontheimer","year":"1999","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2021.102757_bb0120","article-title":"Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis","volume":"8","author":"Gordon","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.autrev.2021.102757_bb0125","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1136\/ard.2006.058644","article-title":"Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies","volume":"66","author":"Barbasso Helmers","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2021.102757_bb0130","first-page":"244","article-title":"Effectiveness of intravenous immunoglobulins in polymyositis and dermatomyositis. An open trial in 15 patients","volume":"20","author":"Cherin","year":"1991","journal-title":"Presse Med"},{"key":"10.1016\/j.autrev.2021.102757_bb0135","first-page":"0","article-title":"Subcutaneous immunoglobulin G in idiopathic inflammatory myopathies\u202f: therapeutic implications","volume":"16","author":"Gelardi","year":"2014","journal-title":"Imaj"},{"key":"10.1016\/j.autrev.2021.102757_bb0140","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/art.10794","article-title":"Interstitial lung disease in polymyositis and dermatomyositis","volume":"47","author":"Marie","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2021.102757_bb0145","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1002\/acr.20325","article-title":"Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: a series of 73 patients","volume":"62","author":"Marie","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.autrev.2021.102757_bb0150","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s10067-012-1940-5","article-title":"Intravenous immunoglobulin therapy in adult patients with polymyositis\/dermatomyositis: a systematic literature review","volume":"31","author":"Wang","year":"2012","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2021.102757_bb0155","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/jnnp.65.1.107","article-title":"Immunoglobulin therapy in inflammatory myopathies","volume":"65","author":"Mastaglia","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2021.102757_bb0160","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1136\/annrheumdis-2017-211400","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: an International Myositis Assessment and Clinical Studies Group\/Paediatric Rheu","volume":"76","author":"Aggarwal","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2021.102757_bb0165","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1002\/art.40320","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology Classification Criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"69","author":"Lundberg","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2021.102757_bb0170","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1136\/ard.61.1.37","article-title":"Cyclosporin A and intravenous immunoglobulin treatment in polymyositis\/dermatomyositis","volume":"61","author":"Danieli","year":"2002","journal-title":"Ann Rheum Dis"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997221000161?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997221000161?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:22:34Z","timestamp":1761600154000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997221000161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S1568997221000161"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2021.102757","relation":{},"ISSN":["1568-9972"],"issn-type":[{"type":"print","value":"1568-9972"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real life picture of the use of intravenous immunoglobulins in idiopathic inflammatory myopathies: Results of a multicentric study","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2021.102757","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102757"}}